159 related articles for article (PubMed ID: 33216223)
21. Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies.
De Stefano N; Sormani MP; Giovannoni G; Rammohan K; Leist T; Coyle PK; Dangond F; Keller B; Alexandri N; Galazka A
Mult Scler; 2022 Jan; 28(1):111-120. PubMed ID: 33969750
[TBL] [Abstract][Full Text] [Related]
22. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
Giovannoni G; Cook S; Rammohan K; Rieckmann P; Sørensen PS; Vermersch P; Hamlett A; Viglietta V; Greenberg S;
Lancet Neurol; 2011 Apr; 10(4):329-37. PubMed ID: 21397565
[TBL] [Abstract][Full Text] [Related]
23. Promising outcomes from Phase III CLARITY study for the treatment of multiple sclerosis announced.
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):198. PubMed ID: 19527090
[No Abstract] [Full Text] [Related]
24. Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum.
Louapre C; Maillart E; Roux T; Pourcher V; Bussone G; Lubetzki C; Papeix C
Rev Neurol (Paris); 2020 Jun; 176(6):523-525. PubMed ID: 32362357
[No Abstract] [Full Text] [Related]
25. Remission of early persistent cladribine-induced neutropenia after filgrastim therapy in a patient with Relapsing - Remitting Multiple Sclerosis.
Maniscalco GT; Annunziata M; Ranieri A; Alfieri G; Renna R; Iorio WD; Guarcello G; Cerillo I; Improta G; Florio C
Mult Scler Relat Disord; 2020 Aug; 43():102151. PubMed ID: 32417665
[TBL] [Abstract][Full Text] [Related]
26. Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods.
Bell Gorrod H; Latimer NR; Damian D; Hettle R; Harty GT; Wong SL
Adv Ther; 2020 Jan; 37(1):225-239. PubMed ID: 31701485
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England.
Hettle R; Harty G; Wong SL
J Med Econ; 2018 Jul; 21(7):676-686. PubMed ID: 29618273
[TBL] [Abstract][Full Text] [Related]
28. Cladribine to Treat Relapsing Forms of Multiple Sclerosis.
Giovannoni G
Neurotherapeutics; 2017 Oct; 14(4):874-887. PubMed ID: 29168160
[TBL] [Abstract][Full Text] [Related]
29. Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
Comi G; Hartung HP; Kurukulasuriya NC; Greenberg SJ; Scaramozza M
Expert Opin Pharmacother; 2013 Jan; 14(1):123-36. PubMed ID: 23256518
[TBL] [Abstract][Full Text] [Related]
30. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
Mankinen P; Lundström T; Soini E; Sumelahti ML; Ruutiainen J; Niskala U; Järvinen E
Adv Ther; 2020 Feb; 37(2):800-818. PubMed ID: 31873868
[TBL] [Abstract][Full Text] [Related]
31. Cladribine induces long lasting oligoclonal bands disappearance in relapsing multiple sclerosis patients: 10-year observational study.
Rejdak K; Stelmasiak Z; Grieb P
Mult Scler Relat Disord; 2019 Jan; 27():117-120. PubMed ID: 30368223
[TBL] [Abstract][Full Text] [Related]
32. Oral therapy for multiple sclerosis--sea change or incremental step?
Carroll WM
N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
Pinheiro B; Guerreiro R; Costa J; Miguel LS
J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
[No Abstract] [Full Text] [Related]
34. Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis.
Afolabi D; Albor C; Zalewski L; Altmann DR; Baker D; Schmierer K
Mult Scler; 2018 Oct; 24(11):1461-1468. PubMed ID: 28817997
[TBL] [Abstract][Full Text] [Related]
35. Retinal cotton wool spot associated with cladribine therapy for multiple sclerosis.
Gummi R; Walsh RD; Ahmad B
Mult Scler Relat Disord; 2021 Feb; 48():102661. PubMed ID: 33321344
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?
Gelibter S; Orrico M; Filippi M; Moiola L
Mult Scler Relat Disord; 2021 Apr; 49():102775. PubMed ID: 33517176
[No Abstract] [Full Text] [Related]
37. COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis.
Mantero V; Abate L; Basilico P; Balgera R; Salmaggi A; Nourbakhsh B; Cordano C
J Neurol; 2021 Jun; 268(6):2023-2025. PubMed ID: 32588182
[No Abstract] [Full Text] [Related]
38. The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
Rammohan K; Coyle PK; Sylvester E; Galazka A; Dangond F; Grosso M; Leist TP
Drugs; 2020 Dec; 80(18):1901-1928. PubMed ID: 33247831
[TBL] [Abstract][Full Text] [Related]
39. [Cladribine in the treatment of relapsing multiple sclerosis].
Robles-Cedeno R; Ramio-Torrenta L
Rev Neurol; 2018 Nov; 67(9):343-354. PubMed ID: 30350846
[TBL] [Abstract][Full Text] [Related]
40. Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment.
Schönfelder K; Schuh H; Pfister F; Krämer J; Eisenberger U; Skuljec J; Hackert J; Ruck T; Pfeuffer S; Fleischer M; Gäckler A; Hagenacker T; Kribben A; Meuth SG; Kleinschnitz C; Pul R
Mult Scler; 2021 Oct; 27(12):1960-1964. PubMed ID: 34165361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]